Distinguished in WT1-Related Wilms Tumor Syndromes

Dr. Daniel M. Geynisman

Oncology | Transplant Surgery
Temple Health
Temple Faculty Practice Plan Inc
3401 N Broad St, 
Philadelphia, PA 
Offers Telehealth

Distinguished in WT1-Related Wilms Tumor Syndromes
Temple Health
Temple Faculty Practice Plan Inc
3401 N Broad St, 
Philadelphia, PA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Daniel Geynisman is an Oncologist and a Transplant Surgeon in Philadelphia, Pennsylvania. Dr. Geynisman is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Renal Cell Carcinoma (RCC), Muscle Invasive Bladder Cancer, Bladder Cancer, Nephrectomy, and Orchiectomy.

His clinical research consists of co-authoring 170 peer reviewed articles and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Oncology
Transplant Surgery
Licenses
Internal Medicine in PA
Hospital Affiliations
Chester County Hospital
Temple University Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Capital Blue Cross
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Geisinger
  • HMO
  • POS
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health Partners Plans
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
Highmark
  • EPO
  • HMO
  • PPO
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
PA Health and Wellness
  • HMO
  • MANAGED MEDICAID PLAN
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
UPMC
  • EPO
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 12 Less Insurance Carriers -

Locations

TEMPLE FACULTY PRACTICE PLAN INC
3401 N Broad St, Philadelphia, PA 19140
Call: 215-707-5030

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


8 Clinical Trials

Phase III Randomized Adjuvant Study of Pembrolizumab in muScle invaSive and locAlly aDvanced urOthelial caRcinoma (AMBASSADOR) Versus Observation
Phase III Randomized Adjuvant Study of Pembrolizumab in muScle invaSive and locAlly aDvanced urOthelial caRcinoma (AMBASSADOR) Versus Observation
Enrollment Status: Active_not_recruiting
Publish Date: October 09, 2025
Intervention Type: Other, Biological, Procedure
Study Drug: Pembrolizumab
Study Phase: Phase 3
A Randomized, Phase II Efficacy Assessment of Multiple MET Kinase Inhibitors (Cabozantinib [NSC #761968], Crizotinib [NSC #749005], Savolitinib [NSC #785348], and Sunitinib [NSC #736511]) in Metastatic Papillary Renal Carcinoma (PAPMET)
A Randomized, Phase II Efficacy Assessment of Multiple MET Kinase Inhibitors (Cabozantinib [NSC #761968], Crizotinib [NSC #749005], Savolitinib [NSC #785348], and Sunitinib [NSC #736511]) in Metastatic Papillary Renal Carcinoma (PAPMET)
Enrollment Status: Completed
Publish Date: January 13, 2025
Intervention Type: Procedure, Drug
Study Drugs: Cabozantinib S-Malate, Crizotinib, Savolitinib, Sunitinib Malate
Study Phase: Phase 2
A Phase II Trial of Risk Enabled Therapy After Initiating Neoadjuvant Chemotherapy for Bladder Cancer (RETAIN BLADDER)
A Phase II Trial of Risk Enabled Therapy After Initiating Neoadjuvant Chemotherapy for Bladder Cancer (RETAIN BLADDER)
Enrollment Status: Active_not_recruiting
Publish Date: December 24, 2024
Intervention Type: Drug, Procedure, Radiation
Study Drugs: Methotrexate, Vinblastine, Doxorubicin, Cisplatin, 5-Fluorouracil, Mitomycin C
Study Phase: Phase 2
A Phase 2, Single Arm Study of CG0070 Combined With Pembrolizumab in Patients With Non Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guerin (BCG)
A Phase 2, Single Arm Study of CG0070 Combined With Pembrolizumab in Patients With Non Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guerin (BCG)
Enrollment Status: Completed
Publish Date: September 25, 2024
Intervention Type: Biological, Other
Study Drugs: Engineered Oncolytic Adenovirus, Pembrolizumab, N-Dodecyl-B-D-Maltoside
Study Phase: Phase 2
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Trial Comparing CB-839 in Combination With Cabozantinib (CB-Cabo) vs. Placebo With Cabozantinib (Pbo-Cabo) in Patients With Advanced or Metastatic Renal Cell Carcinoma (RCC)
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Trial Comparing CB-839 in Combination With Cabozantinib (CB-Cabo) vs. Placebo With Cabozantinib (Pbo-Cabo) in Patients With Advanced or Metastatic Renal Cell Carcinoma (RCC)
Enrollment Status: Completed
Publish Date: March 20, 2023
Intervention Type: Drug
Study Drugs: CB-839, Cabozantinib
Study Phase: Phase 2
A Phase II Study of Sporadic Angiomyolipomas (AMLs) Growth Kinetics While on Everolimus Therapy
A Phase II Study of Sporadic Angiomyolipomas (AMLs) Growth Kinetics While on Everolimus Therapy
Enrollment Status: Terminated
Publish Date: December 15, 2022
Intervention Type: Drug
Study Phase: Phase 2
A Randomized, Double-blinded, Phase II Study of Maintenance Pembrolizumab Versus Placebo After First-Line Chemotherapy in Patients With Metastatic Urothelial Cancer: Hoosier Cancer Research Network GU14-182
A Randomized, Double-blinded, Phase II Study of Maintenance Pembrolizumab Versus Placebo After First-Line Chemotherapy in Patients With Metastatic Urothelial Cancer: Hoosier Cancer Research Network GU14-182
Enrollment Status: Completed
Publish Date: September 30, 2022
Intervention Type: Other, Drug
Study Phase: Phase 2
Phase I/II Study of Ixazomib With Pegylated IFN-alpha 2b (pIFN) in Metastatic Renal Cell Carcinoma (mRCC)
Phase I/II Study of Ixazomib With Pegylated IFN-alpha 2b (pIFN) in Metastatic Renal Cell Carcinoma (mRCC)
Enrollment Status: Terminated
Publish Date: September 26, 2019
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
View 7 Less Clinical Trials

170 Total Publications

Prostate Cancer 2025.
Prostate Cancer 2025.
Journal: Journal of the National Comprehensive Cancer Network : JNCCN
Published: October 09, 2025
View All 170 Publications
Similar Doctors
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Elizabeth R. Plimack
Oncology | Transplant Surgery
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Elizabeth R. Plimack
Oncology | Transplant Surgery

Temple Faculty Practice Plan Inc

3401 N Broad St, 
Philadelphia, PA 
 (0.1 miles away)
215-707-5030
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Elizabeth Plimack is an Oncologist and a Transplant Surgeon in Philadelphia, Pennsylvania. Dr. Plimack is rated as an Elite provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. Her top areas of expertise are Renal Cell Carcinoma (RCC), Muscle Invasive Bladder Cancer, Bladder Cancer, Nephrectomy, and Orchiectomy.

Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Naomi B. Haas
Oncology
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Naomi B. Haas
Oncology

Abramson Cancer Center Perelman 2nd Floor West

3400 Civic Center Boulevard, West Pavilion, 2nd Floor, 
Philadelphia, PA 
 (4.6 miles away)
215-615-5858
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Naomi Haas is an Oncologist in Philadelphia, Pennsylvania. Dr. Haas is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. Her top areas of expertise are Renal Cell Carcinoma (RCC), Chromophobe Renal Cell Carcinoma, Clear Cell Sarcoma, and WT1-Related Wilms Tumor Syndromes. Dr. Haas is currently accepting new patients.

Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Matthew R. Zibelman
Oncology | Transplant Surgery
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Matthew R. Zibelman
Oncology | Transplant Surgery

Temple Faculty Practice Plan Inc

3401 N Broad St, 
Philadelphia, PA 
 (0.1 miles away)
215-707-5030
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Matthew Zibelman is an Oncologist and a Transplant Surgeon in Philadelphia, Pennsylvania. Dr. Zibelman is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Renal Cell Carcinoma (RCC), Muscle Invasive Bladder Cancer, Bladder Cancer, Nephrectomy, and Endoscopy.

VIEW MORE WT1-RELATED WILMS TUMOR SYNDROMES DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Geynisman's expertise for a condition
ConditionClose
  • Elite
  • Bladder Cancer
    Dr. Geynisman is
    Elite
    . Learn about Bladder Cancer.
    See more Bladder Cancer experts
  • Muscle Invasive Bladder Cancer
    Dr. Geynisman is
    Elite
    . Learn about Muscle Invasive Bladder Cancer.
    See more Muscle Invasive Bladder Cancer experts
  • Renal Cell Carcinoma (RCC)
    Dr. Geynisman is
    Elite
    . Learn about Renal Cell Carcinoma (RCC).
    See more Renal Cell Carcinoma (RCC) experts
  • Urothelial Cancer
    Dr. Geynisman is
    Elite
    . Learn about Urothelial Cancer.
    See more Urothelial Cancer experts
  • Distinguished
  • Adult Soft Tissue Sarcoma
    Dr. Geynisman is
    Distinguished
    . Learn about Adult Soft Tissue Sarcoma.
    See more Adult Soft Tissue Sarcoma experts
  • Chromophobe Renal Cell Carcinoma
    Dr. Geynisman is
    Distinguished
    . Learn about Chromophobe Renal Cell Carcinoma.
    See more Chromophobe Renal Cell Carcinoma experts
  • Clear Cell Sarcoma
    Dr. Geynisman is
    Distinguished
    . Learn about Clear Cell Sarcoma.
    See more Clear Cell Sarcoma experts
  • Familial Prostate Cancer
    Dr. Geynisman is
    Distinguished
    . Learn about Familial Prostate Cancer.
    See more Familial Prostate Cancer experts
  • Familial Wilms Tumor 2
    Dr. Geynisman is
    Distinguished
    . Learn about Familial Wilms Tumor 2.
    See more Familial Wilms Tumor 2 experts
  • Non-Muscle Invasive Bladder Cancer
    Dr. Geynisman is
    Distinguished
    . Learn about Non-Muscle Invasive Bladder Cancer.
    See more Non-Muscle Invasive Bladder Cancer experts
View All 9 Distinguished Conditions
  • Advanced
  • Choriocarcinoma
    Dr. Geynisman is
    Advanced
    . Learn about Choriocarcinoma.
    See more Choriocarcinoma experts
  • Penile Cancer
    Dr. Geynisman is
    Advanced
    . Learn about Penile Cancer.
    See more Penile Cancer experts
  • Teratoma of the Mediastinum
    Dr. Geynisman is
    Advanced
    . Learn about Teratoma of the Mediastinum.
    See more Teratoma of the Mediastinum experts
  • Testicular Cancer
    Dr. Geynisman is
    Advanced
    . Learn about Testicular Cancer.
    See more Testicular Cancer experts
  • Upper Tract Urothelial Carcinoma (UTUC)
    Dr. Geynisman is
    Advanced
    . Learn about Upper Tract Urothelial Carcinoma (UTUC).
    See more Upper Tract Urothelial Carcinoma (UTUC) experts
  • Experienced
  • Adrenal Cancer
    Dr. Geynisman is
    Experienced
    . Learn about Adrenal Cancer.
    See more Adrenal Cancer experts
  • Adrenocortical Carcinoma
    Dr. Geynisman is
    Experienced
    . Learn about Adrenocortical Carcinoma.
    See more Adrenocortical Carcinoma experts
  • Bone Tumor
    Dr. Geynisman is
    Experienced
    . Learn about Bone Tumor.
    See more Bone Tumor experts
  • Gallbladder Adenocarcinoma
    Dr. Geynisman is
    Experienced
    . Learn about Gallbladder Adenocarcinoma.
    See more Gallbladder Adenocarcinoma experts
  • Gallbladder Cancer
    Dr. Geynisman is
    Experienced
    . Learn about Gallbladder Cancer.
    See more Gallbladder Cancer experts
  • Hereditary Neuroblastoma
    Dr. Geynisman is
    Experienced
    . Learn about Hereditary Neuroblastoma.
    See more Hereditary Neuroblastoma experts
View All 20 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile
For Patients
  • Our Story
  • How MediFind Works
  • Conditions A-Z
  • Doctor Directory
  • Symptoms Directory
  • Procedures Directory
  • Treatment Directory
  • Drug Directory
  • Infusion Center Finder
  • FAQ
  • Contact Us
For Providers and Practices
  • Claim Your Profile
  • Newsroom
Business Solutions
  • Provider
  • Network Solutions
Additional Resources
  • Consumer Health Data Privacy Policy
  • Privacy Policy
  • Terms of Use
  • Advertising Policy
  • Content Policy
Subscribe to our newsletter

Sign up to stay informed about MediFind and get wellness sent your way.

Close

    By subscribing, I agree to MediFind's Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.

    Bullet PinMediFind
    Follow us on
    This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.
    © 2025 All Rights Reserved